But in some patients, thiazides are not effective; in others they lower blood pressure for a while and then stop working. The reasons for this have remained a mystery. Now, a new study by researchers at the University of Maryland School of Medicine (UM SOM) has revealed a key mechanism for this failure.
Paul Welling, MD, a professor of physiology at the school, and his post-doctoral fellow, P. Rick Grimm, PhD, found the specific genes and pathways used by the kidneys to compensate for thiazides’ activity. The paper was published in the latest issue of the journal Journal of Clinical Investigation. The research was done in conjunction with scientists at Vanderbilt University and Emory University.
“This is the first time we really understand how this process works,” said Dr. Welling, an expert on potassium and sodium balance, kidney disease and hypertension. “It’s as if the kidney knows that it’s losing too much salt and activates mechanisms to retain salt in other ways.”
Thiazides work by inhibiting the movement of salt through the kidney, causing the kidneys to expel salt and water. Salt often raises blood pressure by increasing the amount of water in the vascular system; over time, this fluid puts pressure on the heart and blood vessels, and can cause hypertension. The kidney counteracts the drugs’ effect by retaining more salt, keeping blood pressure high.
Dr. Welling and his collaborators studied an animal model that was genetically engineered to inhibit salt retention, mimicking the effect of thiazides. Using sophisticated technology to track genetic changes in these animals, they found that nearly 400 key genes change their activity to help regulate how the kidneys handle salt. Once activated, these genes worked together, acting on three different pathways related to salt retention. In short these genes increased the body’s ability to hold onto salt, shedding light on how the system can react to thiazides. The interaction of these genes and pathways had not been elucidated in detail before.
The new work has important implications and reveals new possibilities for patients with high blood pressure. Dr. Welling says it may now be possible to begin developing drugs that affect the mechanisms through which the body counteracts thiazides. These drugs might eventually be used alongside thiazides, or might be used on their own.
In addition, the researchers have identified a molecule that increases in the urine when the kidney is working to counteract thiazides. Dr. Welling and his colleagues are now investigating the possibility of using this molecule as a “biomarker,” allowing doctors to quickly and easily detect when thiazides won’t work, or have stopped working, in a particular patient.
“This new work by Dr. Welling is a powerful example of the strong links between basic research and clinical results,” said Dean E. Albert Reece, MD, PhD, MBA, who is also the vice president for Medical Affairs, University of Maryland, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean of the School of Medicine. “Now that we know more about these novel pathways and processes, we can begin to find new ways to help patients with high blood pressure.”
The research was funded by the National Institute of Diabetes, Digestive and Kidney Diseases of the National Institutes of Health.
About the University of Maryland School of Medicine
The University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland and is an integral part of the 11-campus University System of Maryland. Located on the University of Maryland’s Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide a research-intensive, academic and clinically based education. With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S. with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the nation, but also has a global presence, with research and treatment facilities in more than 35 countries around the world.
MEDIA CONTACT
Register for reporter access to contact detailsCITATIONS
Journal of Clinical Investigation
RSS